Behavioral Health Business: Why 2023 Could be a Pivotal Year for Psychedelic-Assisted Treatment

Summary: Behavioral Health Business publishes an overview of the increasing popularity of psychedelics due largely to the promising psychedelic-assisted research results taking place. Author Laura Lovett highlights MAPS-sponsored psychedelic research and how “The industry is closely watching” MAPS’ research on MDMA-assisted therapy for PTSD. “In 2022, MAPS completed its second Phase 3 trial on MDMA to support the substance’s FDA approval,” writes Lovett. “Some industry insiders see this as the research that will lead to the first FDA clearance.”

Originally appearing here (Archived)